Portal de Periódicos da CAPES

Clinical Safety of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX®) in Pediatric and Nonpediatric Patients With Bacterial Conjunctivitis

2005; Elsevier BV; Volume: 50; Issue: 6 Linguagem: Inglês

10.1016/j.survophthal.2005.05.004

1879-3304

Lewis H. Silver, Adrienne M. Woodside, Dawnelle B. Montgomery,

Antibiotics Pharmacokinetics and Efficacy

Five independent, multicentered, double-masked, parallel, controlled studies were conducted to determine the safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Patients were randomized into one of two treatment groups in each study and received either moxifloxacin ophthalmic solution 0.5% b.i.d. or t.i.d. or a comparator. A total of 1,978 patients (918 pediatric and 1,060 nonpediatric) was evaluable for safety. The most frequent adverse event in the overall safety population was transient ocular discomfort, occurring at an incidence of 2.8%, which was similar to that observed with the vehicle. No treatment-related changes in ocular signs or visual acuity were observed with moxifloxacin ophthalmic solution 0.5%, except for one clinically relevant change in visual acuity. Thus, based upon a review of adverse events and an assessment of ocular parameters, moxifloxacin ophthalmic solution 0.5% formulated without the preservative, benzalkonium chloride, is safe and well tolerated in pediatric (3 days-17 years of age) and nonpediatric (18-93 years) patients with bacterial conjunctivitis.